Lv1
40 积分 2023-09-05 加入
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
5天前
已完结
Mycophenolate mofetil: An update
6天前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
7天前
已完结
Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial
7天前
已完结
Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial
7天前
已完结
Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies
9天前
已完结
Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis
23天前
已完结
Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors
23天前
已完结
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
23天前
已完结
Comments on the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for anticoagulant therapy in patients with membranous nephropathy
1个月前
已完结
皖公网安备34019202002308
